Wanbury Peer Comparison

NSE: WANBURY | BSE: 524212

₹197.99

₹-1.51 (-0.76%)

As on 01-Oct-2026IST

Market cap

₹696 Cr

Revenue (TTM)

₹653 Cr

P/E Ratio

12.5

P/B Ratio

4.7

Div. Yield

0 %

Edit

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	696	33,904	26,327	27,051	26,160
Revenue (₹ Cr)	653	3,564	9,205	1,936	1,462
Net Profit (₹ Cr)	55.89	414.00	-371.81	288.22	387.35
Net Margin (%)	8.55	11.23	-3.93	14.79	26.01
RoE (%)	48.51	8.38	-3.85	29.77	25.18
Price to Earnings	12.45	82.89	--	93.86	67.73
Price-To-Book	4.74	6.73	3.29	20.15	15.16

Income Statement (₹ Cr)

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	650.27	3,373.00	8,869.08	1,753.96	1,339.37
Total Income	832.41	3,510.00	9,111.51	1,762.66	1,380.95
Total Expenditure	724.71	2,747.00	7,976.59	1,354.69	858.97
EBITDA	-74.44	626.00	892.49	399.26	480.40
Depreciation	14.31	227.00	831.24	45.26	35.99
EBIT	-88.76	399.00	61.25	354.00	444.41
Interest	29.98	213.00	340.80	42.17	3.27
Other Income	182.14	137.00	242.43	8.70	41.59
Exceptional Items	-3.60	-85.00	-196.14	--	--
Profit before Tax	59.80	238.00	-176.06	320.53	482.73
Provision for Tax	-6.33	39.00	149.88	73.80	126.36
Profit after Tax	66.13	199.00	-325.94	246.74	356.37

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	144.45	4,940.00	8,162.62	1,288.82	1,653.56
Minority Interest	0.00	341.00	--	0.00	57.19
Non-Current Liabilities	157.98	1,235.00	4,529.41	189.02	42.40
Current Liabilities	201.04	1,622.00	4,874.74	835.87	230.81
Total Liabilities	517.67	8,578.00	17,723.32	2,326.71	1,983.96

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	264.91	5,441.00	10,258.66	631.90	1,102.69
Current Assets	238.56	2,606.00	7,308.11	1,681.81	881.27
Total Assets	517.67	8,578.00	17,723.32	2,326.71	1,983.96
Total Debt*	215.45	2,125.00	5,495.48	259.37	26.49
Net Current Assets	37.52	984.00	2,433.37	845.94	650.46
Contingent Liabilities	121.89	768.26	95.72	19.09	17.25

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	31.53	390.00	1,652.60	205.05	292.17
Cash Flow from Investing Activities	-56.40	-241.00	-826.03	-409.72	-265.94
Cash from Financing Activities	22.42	-54.00	-38.98	283.07	4.10
Net Cash Inflow / Outflow	-2.45	95.00	787.59	78.39	30.33

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	30.31	6.79	1.24	29.22	32.42
ROE (%)	67.87	4.29	-4.04	27.84	24.08
ROA (%)	14.53	2.53	-1.98	13.11	20.17
EBIT Margin (%)	16.56	22.62	12.80	23.26	38.97
Net Margin (%)	7.95	5.67	-3.58	14.00	25.81
Cash Profit Margin (%)	12.27	10.98	4.80	7.71	29.29

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	8.47	11.99	-3.08	36.57	33.02
EBIT Growth (%)	34.76	67.69	-28.15	52.29	109.63
Net Profit Growth (%)	116.62	449.12	-457.66	83.64	122.15
EPS Growth (%)	103.18	553.20	-456.91	71.44	348.92
Book Value Growth (%)	179.06	13.47	0.33	144.31	26.03

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	11.76	89.54	0.00	51.69	58.79
Price / Book Value	5.42	3.87	2.24	10.14	12.69
Dividend Yield (%)	0.00	0.00	0.00	0.19	0.10
EV/EBITDA	9.15	27.45	19.72	31.05	39.75
Market Cap (₹ Cr)	777.59	19,071.62	18,108.89	12,753.19	20,944.75

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	1.50	0.43	0.68	0.21	0.02
Short term debt to equity ratio	0.19	0.09	0.09	0.05	0.02
Current Ratio	1.19	1.61	1.50	2.01	3.82
Quick Ratio	0.93	1.06	0.87	1.14	2.82
Interest Coverage	3.00	2.12	0.48	8.60	148.71

	Wanbury	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	22.03	17.43	24.33	29.00	27.07
Asset Turnover	1.44	0.49	0.64	2.01	0.76
Receivable days	71.68	58.75	78.20	40.13	88.98
Inventory Days	24.59	75.82	93.30	60.29	56.04
Payable days	162.17	186.21	226.14	232.47	99.95
Cash Conversion Cycle	-65.90	-51.64	-54.64	-132.04	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.